Latest News

Nic Dracopoli, Ph.D. Joins GenPro’s Scientific Advisory Board

Nic Dracopoli, Ph.D. Joins GenPro’s Scientific Advisory Board

Newark, Delaware – Nicholas (Nic) Dracopoli, Ph.D, an experienced leader in oncology translation research, biomarkers and diagnostics has joined GenPro’s Scientific Advisory Board as the outside lead.

According to Nic, “What captured my interest is GenPro’s science and technology’s ability to rapidly discover a powerful new category of phenotypic biomarkers based on epigenetic responses to different cancers and diseases. There is a huge unmet clinical need in the exploding immuno-oncology field and across the disease spectrum for precision biomarkers that mutation markers cannot easily address. GenPro’s immune-system derived EpiMarkers are well positioned to exploit this opportunity.”

Read More

GenPro and Delaware's Helen F. Graham Cancer Center Discover Novel EpiMarker

HemOnc Feb 2018 - GenPro & Delaware's Helen F. Graham Cancer Center Discover novel EpiMarker with Potential to Predict Invasive vs Non-invasive DCIS Breast Cancer. Click Here for Article.

​GenPro to Present at Biotech Showcase™ Annual Conference ​o​n January 9, 2018

GenPro, a precision heath solutions company pioneering the discovery and commercialization of a new class of biomarkers, epigenetic biomarkers, from blood samples and their translation into actionable assays and information to enable biopharma companies focused on immuno-oncology to dramatically improve the selection of patients into their clinical trials who will respond to their new immuno-therapeutics today announced that its Chairman, CEO and Co-founder, Jeb Connor, will present at the Biotech Showcase ™ 2018 Conference in San Francisco, January 8–10.

Read More

PharmaTech Outlook Selects GenPro to be among 2017's Top 10

PharmaTech Outlook Selects GenPro to be Among 2017's Top 10 Solution Providers to Biopharma Discovery and Development Organizations - November 2017. Details can be found at: 2017 Top 10

USA Today Reports on Christiana Care Collaboration with GenPro

USA Today Reports...Christiana Care Health System's Center for Translational Cancer Research in Collaboration with GenPro Discover Epigenetic Biomarker-Enabled Blood Test to Prevent Overtreatment of Early Stage Breast Cancer - October 2017.

GenPro and Helen F. Graham Cancer Center Present A Novel Epigenetic Biomarker Discovery Approach to a Potential Prognostic Marker for Triple Negative Breast Cancer at NAACR Conference in Washington DC on April 1-4, 2017

The work will be presented in a poster session at the NAACR Conference in Washington DC on Tuesday, April 4, 2017 from 8:00AM - Noon in the poster area in Halls A-C of the Convention Center. It is Section 15, Poster #30, Abstract #3369 which is part of the Epigenetics 3 Section of the Molecular and Cellular Biology & Genetics Session. The project is titled, "Epigenetic DNA Methylation Profiling of Triple Negative Breast Cancer: A Quantitative NGS Approach".

Read More

GenPro adds Two Esteemed Scientists to Scientific Advisory Board

Two renowned leaders in oncology epigenetics recently joined Genome Profiling’s (GenPro’s) Scientific Advisory Board. Christopher Mason, Ph.D., is Assistant Professor of Integrative Functional Genomics, Clinical Genetics and Synthetic Biology at Weill Cornell Medical College in New York. Ajay Goel, Ph. D. has also joined the GenPro Scientific Advisory Board. Dr. Goel is Professor and Director of Baylor Health's Scott and White Center for Gastrointestinal Research and the Center for Translational Genomics and Oncology.

Read More

GenPro publishes EpiMarker feasibility study revealing distinct epigenetic signature of Parkinson's Disease in blood.

Epigenetics is a rapidly developing field focused on deciphering chemical fingerprints that accumulate on human genomes over time. In this paper, GenPro reports a novel quantification methodology for computationally reconstructing site-specific CpG methylation status from next generation sequencing (NGS) data using methyl-sensitive restriction endonucleases (MSRE). In this pilot proof-of-concept study we quantify and compare DNA methylation in blood serum of individuals with Parkinson’s Disease relative to matched healthy blood profiles. Even with a small study of only six samples, a high degree of statistical discrimination was achieved based on CpG methylation profiles between groups, with 1008 statistically different CpG sites (p <0.0025, after false discovery rate correction). The future need for precision diagnostics now requires more tools for exploring epigenetic processes that may be linked to cellular dysfunction and subsequent disease progression. The paper, "Epigenetic DNA Methylation Profiling with MSRE: A Quantitative NGS Approach Using a Parkinson's Disease Test Case", is an open access publication and available at Frontiers in Genetics 2016:00191.

Read More

GenPro presents azacitidine efficacy study to identify epigenetic predictors of Responder vs Non-Responder AML/MDS patients.

Genome Profiling, LLC today announced that data from the company’s methylation quantification technology and its successful result in stratifying pre-treatment responders vs non-responders to Vidaza treated High-Risk MDS and AML Patients, will be presented at the 2016 American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, December 3-6, 2016. The work was conducted as a collaborative study with the H. Lee Moffitt Cancer Center, Tampa, FL.

Read More

GenPro Selected to Lead Epigenetic Profiling on Multi-Company Multi-Institution Team Formed to Discover New Precision Medicine Hypotheses for Undiagnosed Diseases

Genome Profiling, LLC (GenPro) was recently selected to participate and collaborate with four leading precision medicine technology providers and prominent experts from medical centers and universities across the country in the Undiagnosed Disease (UnDx) Consortium to produce new diagnostic and treatment hypotheses for an initial set of six patients struggling with undiagnosed diseases. GenPro will be providing the epigenetic profiling expertise within the multidisciplinary precision medicine approach that, combined with gene sequencing provided by Illumina, is tasked to elucidate new insights into causes and remedies for these difficult medical cases.

Read More

Dr. Adam Marsh, Genome Profiling’s CSO and Co-Founder, will present at the Eighth Annual Next Generation Dx Summit in Washington DC (August 22-26, 2016)

Genome Profiling, LLC (GenPro), a molecular information company focused on discovering novel epigenetic biomarkers and translating them into new clinically valuable precision assays, and new insights into pathways, MOA’s, and potential therapeutic targets, announced that Adam Marsh, Ph. D., Chief Science Officer and Co-Founder, will present recent data illuminating the efficacy of epigenetic biomarker discovery and the game-changing potential they can deliver across many diseases and applications during the Eighth Annual Next Generation Dx Summit held in Washington DC on August 22-26 at 12:30 pm in the “Predictive Cancer Biomarkers” symposia.

Read More

Genome Profiling’s CSO and Co-Founder, Dr. Adam Marsh, to Present at The Biomarker Conference in San Diego, February 18 – 19, 2016

Adam Marsh, Ph. D, Chief Science Officer and Co-Founder of Genome Profiling, LLC, will present novel data demonstrating the potential power of epigenetic biomarkers to deliver new clinical value for Companion Diagnostics Applications during The Biomarker Conference, at the Fourpoints by Sheraton Conference Center in San Diego on February 18 – 19, 2016 at 10:30 am in the “Novel Technologies and Approaches” session.

Read More

Dr. Adam Marsh of Genome Profiling, LLC to Present at the Cancer Diagnostics Conference in San Francisco on November 16, 2015

Genome Profiling CSO Adam Marsh will be one of the distinguished speakers at the Cancer Diagnostics Conference '15 happening in San Francisco. Dr. Marsh will deliver the presentation, "Breakthrough Technology for Non-Bisulfite Epigenetic Profiling of DNA Methylation Enables Epigenetic Diagnostic Biomarker Discovery", that is scheduled on November 16th at 1:30 PM in the Spring Room at Hotel Kabuki.

Read More


On July 19th, 2015, an interview with the executive team from GenPro, LLC was published in USA TODAY.

Read More


On July 9th, 2015, Monica Heger from GenomeWeb reported on the presentation that GenPro's Dr. Adam Marsh made at Bio-IT World's and Cambridge Healthtech Institute's Fourth Annual TCGC: The Clinical Genome Conference.

Read More

Dr. Didier Landais joins Genome Profiling, LLC

Didier Landais has joined Genome Profiling, LLC. Dr. Landais will lead GenPro's business development and engagement execution functions. He brings over 25 years of broad international experience leading product development, clinical collaborations, and business development for several well-established biotech and pharmaceutical companies.

Read More

GenPro at Tri-Con 2015

Genome Profiling's Annamarie Pasqualone will deliver a presentation titled “GenPro: Predictive Epigenetic Biomarker Discovery” at the 2015 Molecular Medicine Tri-Con meeting in San Francisco. The presentation will be on Wednesday, February 18 at 3:20 p.m. in the Epigenomics in Disease meeting session.

Read More

Future for Epigenetic Breast Tumor Risk Screening

Genome Profiling CSO Adam Marsh considers the current potential of epigenetic screening tests for breast tumors in his Huffington Post essay “New Approaches for Breast Tumor Diagnostics”. Several recent medical studies indicate that epigenetic profiling of breast tumors may explain and predict how and why different women develop different types of breast tumors. These tumors are variable in their growth rates, response to therapeutics and invasiveness. Epigenetics is beginning to provide a quantifiable measure of how to differentiate these patient risk groups and tumor types.

GenPro in Boston in April

Adam Marsh will be speaking at Bio-IT World's Clinical Genomics 2015 conference, April 21-23 in Boston, MA. Dr. Marsh's presentation is titled “Epigenetic Profiling of DNA Methylation to Identify Breast Tumor Aggressiveness”. Women with triple-negative genotypes (i.e., normal for the 3 common marker mutations for breast cancer) are still at risk for developing aggressive breast tumors. We identify a suite of differentially methylated CpG sites between Normal and Tumor breast tissues using NGS that indicate a high degree of epigenetic conservation among different triple-negative patients who have developed advanced-stage breast tumors. Subtle epigenetic shifts in methylation status may provide a key line of evidence for assessing tumor risk and informing therapy decisions between surgery or non-invasive treatments.